Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia
This research is all about Chronic Myeloid Leukemia (CML). If you have CML and are taking a specific type of medication called a Tyrosine Kinase Inhibitor (TKI), this study wants to understand how other medicines you might be taking, including herbal remedies, could affect your CML treatment. Researchers will carefully check your TKI medication levels to make sure they are working effectively. Sometimes, if the levels aren't quite right, they might suggest changes to your medications or their doses. The goal is to help your CML treatment be as successful as possible, improving your health and ensuring you respond well to the therapies.
At a glance
What is this study about?
This study focuses on a type of blood cancer called Chronic Myeloid Leukemia, often shortened to CML. When you have CML, a specific genetic change causes your body to make too many white blood cells. This condition is usually managed with powerful medications called Tyrosine Kinase Inhibitors, or TKIs for short. These medicines have made a huge difference, helping many people with CML live long, healthy lives, often as long as someone without CML.
The main idea behind this research is to get a clearer picture of how these TKI medications work in your body, especially when you're taking other medicines, vitamins, or even herbal supplements. Sometimes, different drugs can interact with each other, meaning one might make the other less effective or cause unexpected side effects. Researchers will measure the amount of the TKI medication in your blood to ensure it's at the right level to fight your CML effectively. Having the right amount is important because it means the treatment is reaching its full potential.
If the study finds that your TKI levels aren't ideal, or if there are concerns about how your medications might be interacting, the study team might suggest some changes. This could involve adjusting the dose of your TKI or even looking at other medications you're taking. The aim is always to help your CML treatment work as best as it can, ensuring you get the most out of your therapy and continue to manage your CML successfully. It's about personalising your care to get the best health outcome for you.
Key takeaways
- Aims to understand how other medicines affect CML treatment.
- Focuses on checking levels of CML medications (TKIs).
- May lead to adjustments in medication for better results.
- Helps ensure CML treatment is as effective as possible.
- Specifically for adults with CML taking certain TKI drugs.
Who may be eligible?
To join this study, you need to be an adult, 18 years or older, and have Chronic Myeloid Leukemia (CML). You also need to be taking one of the specific CML medications called Tyrosine Kinase Inhibitors (TKIs), such as Imatinib, Nilotinib, Dasatinib, or Bosutinib. Additionally, your CML treatment response, as measured by a molecular test, should be less than 4.5 Loggs, which is a way doctors measure how well your treatment is working.
You would not be able to join if you are unable to make your own medical decisions, either legally or due to a medical or psychological condition. You also cannot participate if you are taking a specific TKI medication called Ponatinib. The study currently requires participants to be able to read and write French, which might exclude some people in the UK.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have Chronic Myeloid Leukemia (CML)?
- Are you currently taking Imatinib, Nilotinib, Dasatinib, or Bosutinib?
- Is your CML treatment response (molecular logarithm) less than 4.5?
- Can you read and write French? (May be a point to clarify with your doctor)
What does participation involve?
If you decide to take part in this study, the main involvement will be carefully reviewing all the medications you currently take. This includes not just prescription drugs, but also over-the-counter medicines, herbal remedies, and any supplements. Doctors will also measure the levels of your CML medication (Tyrosine Kinase Inhibitor) in your blood. If these levels aren't ideal, or if there are concerns about how your medicines might be interacting, the study team might suggest adjusting the dose of some of your medications or making other changes. If any changes are made, your CML medication levels would be re-checked. The total duration of your participation would depend on whether any changes are made and if follow-up checks are needed.
Potential risks and benefits
Locations (1)
- CHU de Saint-EtienneVerified postcodeSaint-Etienne, France· Recruiting
Common questions
What is Chronic Myeloid Leukemia (CML)?
CML is a type of blood cancer where your body makes too many white blood cells due to a genetic change.
What are Tyrosine Kinase Inhibitors (TKIs)?
TKIs are specific medications used to treat CML by targeting the faulty protein that causes the cancer.
Why is it important to check drug levels?
Checking drug levels helps ensure you have enough of the medication in your body for it to work properly against your CML.
Will my medication be changed if I join?
Possibly. If the study identifies potential issues with drug interactions or levels, your medical team might suggest adjustments to your medication or its dose, which you would discuss and agree to.
Is this study taking place in the UK?
The original description mentioned an exclusion criterion related to reading/writing French, which suggests it may not be primarily based in the UK, but discussing with your doctor can clarify international participation.
How to find out more
Elisabeth DAGUENET, doctor of science
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.